Tech Company Financing Transactions

Allozyne Funding Round

MPM Capital, Amgen Ventures and Arch Venture Partners participated in a $30 million Series B funding round for Allozyne. The round was announced on 10/26/2007.

Transaction Overview

Company Name
Allozyne
Announced On
10/26/2007
Transaction Type
Venture Equity
Amount
$30,000,000
Round
Series B
Investors

MPM Capital (Lead Investor) (Michael Steinmetz)

Amgen Ventures

Arch Venture Partners (Robert Nelson)

OVP Venture Partners (Carl Weissman)

Proceeds Purpose
Proceeds from the financing will be used to advance Allozyne's lead product candidate, an improved version of Interferon beta for the treatment for Multiple Sclerosis (MS), into clinical development and through the completion of phase I clinical trials. This funding will also accelerate the preclinical development of a second program as well as further exploit the company's proprietary technology platform.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1600 Fairview Ave. East 300
Seattle, WA 98102
USA
Phone
(206) 518-5700
Website
www.allozyne.com
Email Address
[email protected]
Overview
Allozyne develops technologies that improve the efficacy, safety, dosing, and other characteristics of protein-based therapeutics.
Profile
Allozyne LinkedIn Company Profile
Social Media
Allozyne Company Twitter Account
Company News
Allozyne News
Facebook
Allozyne on Facebook
YouTube
Allozyne on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Meenu Karson
  Meenu Karson LinkedIn Profile  Meenu Karson Twitter Account  Meenu Karson News  Meenu Karson on Facebook
Chief Scientific Officer
Kenneth Grabstein
  Kenneth Grabstein LinkedIn Profile  Kenneth Grabstein Twitter Account  Kenneth Grabstein News  Kenneth Grabstein on Facebook

 

 

Browse more venture capital transactions:

Prev: 10/26/2007: Arteriocyte venture capital transaction
Next: 10/26/2007: Mainstream Data venture capital transaction

 

Share this article

 

Where The Data Comes From

We report on all VC transactions involving tech companies. VC investment data records reported here are derived from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.